Ally Bridge Group’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
DTC
Ally Bridge Group's AXSM Position: Q2 2026 in Review
Ally Bridge Group opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 16,493 shares worth $4.04M. The stake represents 3.57% of the portfolio and ranks #6 among its holdings. This is a return to the name: Ally Bridge Group previously reported a position in AXSM as recently as Q1 2025.
Ally Bridge Group first reported a position in AXSM in Q3 2023 and has held it in 5 quarters since. The position peaked at $8.41M in Q1 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- Ally Bridge Group held 16,493 shares of Axsome Therapeutics worth $4.04M as of Q2 2026.
- Axsome Therapeutics was a new Ally Bridge Group position in Q2 2026.
- Axsome Therapeutics made up 3.57% of Ally Bridge Group's portfolio in Q2 2026, its #6 holding.
- Ally Bridge Group first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 5 quarters since.
- Ally Bridge Group's Axsome Therapeutics position peaked at $8.41M in Q1 2025.
- 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.